Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous solution for subcutaneous injection. It is used to treat acute attacks of hereditary angioedema in patients with a confirmed diagnosis, providing rapid symptom relief.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. The company ensures product integrity through validated cold‑chain logistics and comprehensive quality assurance.

Icatibant Fresenius is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema. - Acute attacks of hereditary angioedema type I: rapid reduction of swelling and pain. - Acute attacks of hereditary angioedema type II: rapid reduction of swelling and pain. - Acute attacks of hereditary angioedema with normal C1‑INH: rapid reduction of swelling and pain.

Common adverse reactions observed with subcutaneous icatibant include injection‑site and systemic events.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Injection site erythema: redness around the injection area. - Injection site swelling: localized edema. - Nausea: feeling of sickness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Angioedema: swelling of face, lips, or throat. - Severe hypotension: marked drop in blood pressure. - Severe injection‑site necrosis: tissue damage at injection site.

Before using icatibant, consider the following safety measures. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Renal impairment: use with caution and monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; monitor for angioedema. - Known hypersensitivity: avoid use in patients with documented allergy to icatibant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effects may raise angioedema risk. - Angiotensin receptor blockers: similar potential for increased bradykinin. - Other bradykinin B2 antagonists: no added therapeutic benefit.

Moderate Interactions (Monitor Closely): - Corticosteroids: may mask signs of infection. - Antihistamines: could interfere with assessment of allergic reactions. - Diuretics: monitor blood pressure and electrolyte balance.